ViiV Healthcare presents three-year switch data for Dovato (dolutegravir/lamivudine) confirming long-term, non-inferior efficacy with no virologic failure versus continuation of TAF-based regimens of at least three drugs

The Phase III TANGO study is the third trial to provide long-term evidence for Dovato, reinforcing its use as a viable switch option for people living with HIV For media and investors only ViiV

Related Keywords

United States ,Brentford ,Hounslow ,United Kingdom ,North Carolina ,Washington ,London ,City Of ,Philadelphia ,Pennsylvania ,Middlesex ,United Kingdom General ,Kimberly Smith ,Kathleen Quinn ,Jeff Mclaughlin ,Mick Readey ,Audrey Abernathy ,Tim Foley ,James Dodwell ,Kostenloser Wertpapierhandel ,Olayemi Osiyemi ,Melinda Stubbee ,Glaxosmithkline ,Nao Research Institute ,Company Annual Report On Form ,Pfizer Inc ,O Medical Services ,Viiv Healthcare ,Head Of Research Development At Viiv Healthcare ,Shionogi Limited ,Tripleo Medical Services ,Research Development ,Per Protocol ,Safety Information ,Fetal Toxicity ,Severe Hepatomegaly ,Virologic Response Due ,Drug Interactions ,Reconstitution Syndrome ,Prescribing Information ,Antiretroviral Pregnancy Registry ,Reproductive Potential ,About Viiv ,Annual Report ,England Wales ,West Road ,Dose Combination ,Based Regimen ,Maintaining Virologic Suppression ,Evaluate Dolutegravir Plus Lamivudine ,Accessed September ,Lviiv ,Healthcare ,Presents ,Three ,Ear ,Switch ,Data ,Novato ,Dolutegravir ,Lamivudine ,Aconfirming ,Song ,Term ,Inferior ,Efficacy ,Irologic ,Failure ,Versus ,Continuation ,Ased ,Regimens ,Least , ,